These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20623260)

  • 1. The use of botulinum toxin a in idiopathic overactive bladder syndrome.
    Gomez CS; Kanagarajah P; Gousse A
    Curr Urol Rep; 2010 Sep; 11(5):353-9. PubMed ID: 20623260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.
    Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE
    Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin treatment for bladder dysfunction.
    Santos-Silva A; da Silva CM; Cruz F
    Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
    Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
    Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin--a new therapeutic agent in girls with non-neurogenic overactive bladder--a case report and review of the literature.
    Kulik-Rechberger B; Piechuta L; Miotła P; Skorupski P; Rechberger T
    Ginekol Pol; 2010 Nov; 81(11):870-3. PubMed ID: 21361152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
    Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
    Krivoborodov GG; Tur EI; Efremov NS
    Urologiia; 2015; (2):31-4. PubMed ID: 26237802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome.
    Bauer RM; Gratzke C; Roosen A; Hocaoglu Y; Mayer ME; Buchner A; Stief CG; May F
    Urol Int; 2011; 86(1):68-72. PubMed ID: 20639617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin injection: a review of injection principles and protocols.
    Rapp DE; Lucioni A; Bales GT
    Int Braz J Urol; 2007; 33(2):132-41. PubMed ID: 17488531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
    Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
    Kuo HC; Liao CH; Chung SD
    Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.
    Dowson C; Khan MS; Dasgupta P; Sahai A
    Nat Rev Urol; 2010 Dec; 7(12):661-7. PubMed ID: 21139642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects of intradetrusor botulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings.
    Caremel R; Courtois F; Charvier K; Ruffion A; Journel NM
    BJU Int; 2012 Jun; 109(11):1698-702. PubMed ID: 21981647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie J; Wilson DI; Herbison GP; Wilson D
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005493. PubMed ID: 17636801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.